Necrosis News and Research

RSS

Study: Mice lacking PARL protein display specific problems in the nervous system reminiscent of Leigh syndrome

Leuven researchers led by professor Bart De Strooper (VIB-KU Leuven) have identified a new role for PARL, a protein that has been linked to Parkinson's disease.

3 Jan 2019

New insights on cellular death mechanisms caused by the loss of neuronal cells and astrocytes

The blood circulation to neurons is affected due to Ischemic, hemorrhagic stroke and subarachnoid hemorrhage stimulation the activation of pathophysiological responses i.e. mitochondrial death pathways, protein misfolding, apoptosis, pyroptosis, necrosis, autophagy, mitophagy, ferritinophagy, excitotoxicity, free radicals release, and inflammation.

31 Dec 2018

Sickest children could benefit from split liver transplants

In a review of registry data for more than 5,300 liver transplants performed in children nationwide, Johns Hopkins Medicine researchers identify the type of patient who is most likely to survive a split liver transplant--receiving only part of a donor's liver--with no additional long-term health risks, which could allow for an increase in the availability of organs.

18 Dec 2018

Russian scientists identify molecular 'switch' that could be target for treatment of allergic asthma

A team of Russian scientists identified the role of the interleukin-6 molecule in the development of allergic asthma. Now it can be a new target for the treatment of this disease. The results are published in Frontiers in Immunology.

17 Dec 2018

Findings may open up new ways to treat dwarfism and other ER-stress-related conditions

Pseudoachondroplasia (PSACH) is a severe inherited dwarfing condition characterized by disproportionate short stature, joint laxity, pain, and early onset osteoarthritis.

12 Dec 2018

ACR and NPF release joint treatment guideline for psoriatic arthritis

The American College of Rheumatology and National Psoriasis Foundation have released a joint treatment guideline for psoriatic arthritis that provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for treatment-naïve patients with active PsA and patients who continue to have active PsA despite treatment.

4 Dec 2018

New ointment for treating brown recluse spider bites is tested on humans

The bite from a brown recluse spider (Loxosceles) can cause skin necrosis, renal failure, and even death. A new ointment is being tested in Brazil, however. Its effects have already been proven in tests conducted in cell cultures and animal models.

29 Nov 2018

New pharmacological agent shows promise for prevention of heart rhythm disorders

A new pharmacological agent demonstrates promising results for the prevention of a wide range of heart rhythm disorders, including both cardiac and brain injury-induced arrhythmias.

15 Nov 2018

Study could provide novel treatment strategy for potentially blinding problem

An enzyme known to help our liver get rid of ammonia also appears to be good at protecting our retina, scientists report.

8 Nov 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.

22 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Researchers use nanoparticles to treat snake bites

Venomous snakebites affect 2.5 million people, and annually cause more than 100,000 deaths and leave 400,000 individuals with permanent physical and psychological trauma each year.

5 Oct 2018

Scripps Research scientists discover role of immune system double agent

Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.

5 Oct 2018

Necrosis News and Research

Study: Mice lacking PARL protein display specific problems in the nervous system reminiscent of Leigh syndrome

New insights on cellular death mechanisms caused by the loss of neuronal cells and astrocytes

Sickest children could benefit from split liver transplants

Russian scientists identify molecular 'switch' that could be target for treatment of allergic asthma

Findings may open up new ways to treat dwarfism and other ER-stress-related conditions

ACR and NPF release joint treatment guideline for psoriatic arthritis

New ointment for treating brown recluse spider bites is tested on humans

New pharmacological agent shows promise for prevention of heart rhythm disorders

Study could provide novel treatment strategy for potentially blinding problem

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Researchers use nanoparticles to treat snake bites

Scripps Research scientists discover role of immune system double agent

Aggressive breast cancer hijacks normal protective physiological process to survive

Aggressive breast cancer cells hijack protective protein to aid growth

Gangrene-causing bacteria show promise as cancer treatment

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

New study links stress with biological disease markers in leukemia patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News